Living Bacteria Engineered to Produce and Deliver Peptide Drugs Inside the Body | Research

The takeaway

Recombinant live biotherapeutics — engineered bacteria that produce and deliver peptide drugs from within the body — represent a new frontier for overcoming peptide stability and delivery challenges.

Living drug factories
Engineered bacteria producing peptide drugs in situ could eliminate injection requirements

What the researchers found

Recombinant live biotherapeutics offer a novel platform for in-body peptide drug biosynthesis and precision delivery, potentially overcoming key limitations of traditional peptide therapeutics.

Why it matters

Most peptide drugs require injections because they're destroyed by digestion. Bacteria engineered to produce peptides inside the body could eliminate injections and enable continuous, targeted drug delivery.

How the study worked

Review chapter covering peptide production technologies, delivery challenges, and the emerging field of engineered live biotherapeutics.

What this study cannot tell us

Largely theoretical with limited clinical data; regulatory challenges for live biotherapeutics are substantial; safety concerns about engineered organisms in the body.

How to read the evidence

Review chapter covering an emerging field — strong conceptual framework with limited clinical validation to date.

When this study was published

Published in 2026, surveying the cutting edge of live biotherapeutic drug delivery.

The bigger picture

This concept merges synthetic biology with pharmacology — instead of manufacturing drugs in factories and injecting them, we could program the body's own microbes to become drug factories, fundamentally changing medicine.

Questions still open

Can engineered bacteria maintain stable peptide production over clinically relevant timeframes?
How will regulators evaluate the safety of living drug-producing organisms inside patients?

Common questions

How can bacteria deliver drugs?

Scientists can engineer bacteria with new DNA instructions to produce therapeutic peptides. When these bacteria are taken orally or placed at a target site, they act as living factories, continuously making and releasing the drug where it's needed.

Could this replace daily insulin injections?

Potentially — if engineered gut bacteria could produce insulin or GLP-1 peptides in response to blood sugar levels, it could dramatically simplify diabetes management. This is still experimental but represents a major research goal.

Read the original research

Recombinant live biotherapeutics: A new frontier in peptide drug biosynthesis and precision delivery.

Progress in molecular biology and translational science, 220, 175-207

View on PubMed ↗Publisher’s paper ↗

Citation

Chawla, Meenal; Bhange, Omkar; Das, Bhabatosh. (2026). Recombinant live biotherapeutics: A new frontier in peptide drug biosynthesis and precision delivery.. Progress in molecular biology and translational science, 220, 175-207. https://doi.org/10.1016/bs.pmbts.2025.12.002